The 36-month beta value for NTLA is at 2.24. Analysts have varying views on the stock, with 18 analysts rating it as a “buy,” 4 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for NTLA is 97.49M, and currently, shorts hold a 29.49% of that float. The average trading volume for NTLA on May 13, 2025 was 3.63M shares.
NTLA) stock’s latest price update
Intellia Therapeutics Inc (NASDAQ: NTLA)’s stock price has plunge by -4.91relation to previous closing price of 8.55. Nevertheless, the company has seen a 12.14% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-12 that Investors who’ve been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.
NTLA’s Market Performance
Intellia Therapeutics Inc (NTLA) has seen a 12.14% rise in stock performance for the week, with a 9.72% gain in the past month and a -11.73% plunge in the past quarter. The volatility ratio for the week is 9.87%, and the volatility levels for the past 30 days are at 8.15% for NTLA. The simple moving average for the past 20 days is 0.77% for NTLA’s stock, with a -43.27% simple moving average for the past 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Wolfe Research repeating the rating for NTLA by listing it as a “Outperform.” The predicted price for NTLA in the upcoming period, according to Wolfe Research is $21 based on the research report published on April 21, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $30. The rating they have provided for NTLA stocks is “Buy” according to the report published on March 05th, 2025.
JP Morgan gave a rating of “Neutral” to NTLA, setting the target price at $13 in the report published on February 28th of the current year.
NTLA Trading at -1.23% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.15% of loss for the given period.
Volatility was left at 8.15%, however, over the last 30 days, the volatility rate increased by 9.87%, as shares surge +7.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.71% lower at present.
During the last 5 trading sessions, NTLA rose by +11.17%, which changed the moving average for the period of 200-days by -69.49% in comparison to the 20-day moving average, which settled at $8.06. In addition, Intellia Therapeutics Inc saw -30.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Bhanji Muna, who sale 265 shares at the price of $8.50 back on Apr 29 ’25. After this action, Bhanji Muna now owns 19,203 shares of Intellia Therapeutics Inc, valued at $2,252 using the latest closing price.
Clark Eliana, the EVP, Chief Technical Officer of Intellia Therapeutics Inc, sale 679 shares at $8.99 during a trade that took place back on Mar 04 ’25, which means that Clark Eliana is holding 95,369 shares at $6,104 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -9.23 for the present operating margin
- 0.87 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -8.97. The total capital return value is set at -0.49. Equity return is now at value -57.92, with -46.84 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -1.66.
Currently, EBITDA for the company is -508.74 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 14.98. The receivables turnover for the company is 6.8for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, Intellia Therapeutics Inc (NTLA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
